Our global survey reveals no cases of insertional mutagenesis following CAR T-cells in pediatric patients challenging concerns of secondary malignancy risk in this population.This underscores the safety of CAR T-cell therapy in this population, but ongoing surveillance required.
No takes yet. Share an insight, caveat, or question.
Lamble et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: